RenuMemo Therapeutics LLC
- Biotech or pharma, therapeutic R&D
RenuMemo Therapeutics is focused on developing a therapeutic drug to treat Alzheimer’s disease across all stages, including mild, moderate, and severe forms. The lead product is an extract derived from medicinal herbs, with identified active ingredients that target different mechanisms of action, including anti-inflammation, beta-amyloid reduction, and neurotransmitter modulation. An open-label Investigator-Initiated Trial is currently being conducted, in which patients across all stages of Alzheimer’s disease are being treated. The mid-term results showed significant improvement in cognitive function, along with a reduction in the biomarker pTau217.
RenuMemo Therapeutics is interested in meeting to discuss the following opportunities:
Partnership opportunity – Collaborate with companies that have the capability to co-develop and register the botanical drug in their respective countries.
Investment opportunity– Participate in Series A funding round to support to complete IIT.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}